research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
Search
for
Sort by
Research
390-420 / 1000+ resultsresearch 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH
Finasteride reduces some inflammation in BPH but not all.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Is tapering and stopping of tofacitinib possible among pediatric and adolescent alopecia areata patients?
Tapering and stopping tofacitinib may be possible for young alopecia areata patients.
research FR-Mesoterapia con dutasterida, una futura alternativa para el tratamiento de la alopecia androgenética
Dutasteride injections may be a future option for treating hair loss.
research THE TREATMENT OF BPH WITH HYPERTENSION
Terazosin hydrochloride helps with BPH and blood pressure, but not more than the control.
research Design, synthesis and anti-tumor evaluation of novel thiohydantoin congeners as androgen receptor antagonists with in vivo study.
A new compound, 3a, effectively fights prostate cancer better than finasteride.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research Apremilast for extensive and treatment-resistant alopecia areata: a retrospective analysis of five patients
Apremilast showed mixed results for treating severe alopecia areata.
research Medikamentöse Therapie des benignen Prostatasyndroms (BPS)
Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
research A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata
Oral cyclosporine is more effective and safer than betamethasone for treating alopecia areata.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Finasteride
research Encephalitis lethargica due to Epstein–Barr virus infection
Finasteride may help reduce tic severity in male Tourette syndrome patients.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Cyproterone acetate as initial treatment and maintenance therapy for hirsutism
Cyproterone acetate is effective for treating hirsutism, but some patients may feel worse on low-dose maintenance therapy.
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production
The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
research The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome
research Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models
Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.
research Trazodone by epigenetic mechanism can reverse the post finasteride syndrome
Trazodone might help reverse post finasteride syndrome.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Inhibitory Effect of Extract of Urtical Mairei Levl on 5α-Reductase Activity
The root extract of Untica mairei Levl may help treat benign prostatic hyperplasia.
research Finasteride-related sexual and neuropsychiatric AEs
research Intralesional pentoxifylline injection in localized alopecia areata
Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.